A biopharmaceutical startup with Cincinnati roots is making plans to go public with an initial offering that could top $180 million, months after inking a nine-figure fundraise that stands as one of the region’s largest.
CinCor Pharma Inc., a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardio-renal diseases, this week launched its IPO roadshow, per a release. The move follows a $143 million Series B raised by the company in October.
Click here to read the complete story.
Story excerpt provided by Cincy Inno.
Written by Liz Engel.
Originally published January 6, 2021.